Alumis

Today, we reported our Q3 2025 financial results and provided highlights of recent progress. Learn more: https://lnkd.in/eJur8Sg7

We’re in New York for the 6th Inflammatory Skin Disease Summit: The Translational Revolution in New York to discuss new developments in the field of inflammatory skin diseases and share a new biomarker analysis on envudeucitinib—our investigational treatment for moderate to severe psoriasis – on November 13. Learn more about the meeting here: https://bit.ly/3XbEfQG

Mark your calendars! Today, we announced our participation in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conference on November 11 and Stifel 2025 Healthcare Conference on November 12. Learn more: https://lnkd.in/eyPNG2t7

Proud to share that The Alumis "Aluminators" laced up their sneakers and joined the recent #WalkToEndLupusNow in San Francisco.   Participating in this walk was more than a team outing—it was a chance to advance our mission beyond the lab and into the lives of those we serve.   A heartfelt thank you to everyone who walked, donated, and cheered us on. Together, we’re taking steps toward greater awareness, stronger community, and lasting impact.

Today, on World Psoriasis Day, we’re reflecting on the power of patient voice.   Last week, our team had the privilege of hearing directly from Howard Chang, a person living with psoriasis. His story —honest, resilient, and deeply human—reminded us that behind every clinical milestone is a lived experience shaped by stigma, systemic symptoms, and emotional complexity.   Howard helped us see that full picture, and we’re grateful for the opportunity to listen and learn.   Let’s keep pushing for awareness, empathy, and action—because understanding the full impact is an important step toward meaningful change.   Follow National Psoriasis Foundation to find resources and tips for living with psoriatic disease.

Alumis is heading to Las Vegas this week for the 2025 Fall Clinical Dermatology Conference. We are sharing a new analysis of STRIDE and 52-week OLE data for our next-generation oral TYK2 inhibitor, envudeucitinib, with a focus on treat-to-target thresholds. This practical approach bridges data with decision-making, ensuring that treatment remains goal-oriented, measurable, and responsive to each patient’s needs. Visit our poster to learn more.

We’re looking forward to attending #ACR25 – an important forum for understanding where the rheumatology field is headed - especially in complex immune-mediated diseases like lupus - and how we can help shape it. See you there! Learn more about our work in lupus: https://bit.ly/EnvuLupus

We're pleased to share that 52-week results from the open-label extension period of the Phase 2 STRIDE study of our oral next-generation TYK2 inhibitor, envudeucitinib, in patients with moderate to severe plaque psoriasis have been published in the Journal of the @American Academy of Dermatology (JAAD). Read the full manuscript here: https://bit.ly/4q6wxob

It’s #BlindnessAwarenessMonth, and this week we’re in Orlando presenting lonigutamab’s potential in thyroid eye disease (TED) at the ASOPRS Fall Symposium and joining the #AAO2025 dialogue. Proud to help shape the future of eye health—alongside a community committed to advancing patient care. See the full ASOPRS symposium program: https://bit.ly/3VEYcPl Learn more about this year’s American Academy of Ophthalmology meeting: https://bit.ly/4pPG578

We’re proud to be part of the dialogue shaping the future of multiple sclerosis (MS) care at #ECTRIMS2025— the premier global event dedicated to comprehensive research and advanced treatment of MS. If you missed our Phase 1 data poster on our differentiated TYK2 inhibitor A-005, you can check it out here: http://bit.ly/42Fjq3m